Home JournalsJournal Details

eISSN: 2051-1426 CAS Zone: Medicine (Zone 1) Emerging Zone: Medicine (Zone 1)

Journal for ImmunoTherapy of Cancer

Abbr. J IMMUNOTHER CANCER

11.7

Latest IF

Recent Articles

METLUNG: plasma metabolomic profiling identifies metabolomic signatures associated with immunotherapy outcomes in non-small cell lung cancer

Lucía-Gozálvez C, Papandreou C, Badia J et al · Vol 14(9): e016077

2026-09-25

SPP1 ⁺ macrophage-induced CD74 ⁺ tumor cells promote adrenocortical carcinoma tumor thrombus via the SPP1/CD44/JAK/STAT signaling

Zhang H, Xu K, Zhen L et al · Vol 14(9): e015080

2026-09-23

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0

Shah N, Craddock C, Gore L et al · Vol 14(9): e015963

2026-09-21

Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment

Zhang M, Barrett K, Carter C et al · Vol 14(9): e015643

2026-09-21

NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma

Li Y, Zhuang X, Tang Y et al · Vol 14(9): e015639

2026-09-21

CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer

Muneer A, Showkatian E, Kitsel Y et al · Vol 14(9): e015014

2026-09-18

CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers

Che X, Yun U, Lee J et al · Vol 14(9): e014131

2026-09-18

LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma

Hou X, Lin L, Zhang P et al · Vol 14(9): e015730

2026-09-15

Epigenetic plus cytokine therapy induces stem-like CD8 ⁺ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance

Minnar C, Miyamoto M, Khelifa A et al · Vol 14(9): e015228

2026-09-12

PLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy

Shafaattalab S, Partin A, Winters A et al · Vol 14(9): e015068

2026-09-12

Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort

Yu H, Li X, Cheng X et al · Vol 14(9): e015705

2026-09-12

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer

Fernández-Luna C, Baena J, Calles A et al · Vol 14(9): e016133

2026-09-12

HIF1A ⁺ CSF3R ⁺ neutrophils-dominated hypoxic niche induced metabolic reprogramming for neoadjuvant therapy resistance in NSCLC

Zhou Y, Liu Z, Kaysar P et al · Vol 14(9): e014772

2026-09-08

Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1 ⁺ CD8 ⁺ T cells

Lin X, Zhang J, Fan Z et al · Vol 14(9): e014273

2026-09-07

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors

Dumbrava E, Oh D, Ryu M et al · Vol 14(9): e014309

2026-09-07

Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity

Ning F, San Andres-Montalvan E, Meyer T et al · Vol 14(9): e014938

2026-09-07

Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients

Vetere G, Osterlund E, Yousef M et al · Vol 14(9): e015414

2026-09-02

Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer

Lian W, Yang H, Zhang Y et al · Vol 14(9): e015037

2026-09-02

Normal-immunopeptidome denominator: a safety atlas for immunotherapies targeting non-canonical and aberrantly expressed tumor antigens

Chen L · Vol 14(9): e016056

2026-09-01

Mechanistic modeling of tumor immune microenvironment reveals strategies to enhance antibody-drug conjugates’ efficacy

Harkos C, Munn L, Stylianopoulos T et al · Vol 14(9): e015357

2026-09-01

Journal Info

Abbr.

J IMMUNOTHER CANCER

CAS Zone

Medicine (Zone 1) · Top

Emerging Zone

Medicine (Zone 1) · Non-Top

Sub-categories

IMMUNOLOGYZone 1ONCOLOGYZone 2

Emerging Categories

ONCOLOGYZone 1IMMUNOLOGYZone 1

Analysis Services

Journal for ImmunoTherapy of Cancer

Contact

WeChat Official Account